Renal Cancer
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
October 30, 2023
Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring.
October 30, 2023
Clinical values of circulating tumor cells count in localized renal cell carcinoma.
October 27, 2023
Simplified PADUA renal (SPARE) nephrometry score validation and long-term outcomes after robot-assisted partial nephrectomy.
October 27, 2023
suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma.
October 26, 2023
Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic.
October 26, 2023
Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
October 23, 2023
Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
October 20, 2023
Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma.
October 19, 2023
A comprehensive prognostic and immunological analysis of telomere-related lncRNAs in kidney renal clear cell carcinoma.
October 19, 2023